Early irAEs are associated with a better outcome after treatment with immunotherapy. We predicted responses to nivolumab by using early irAEs. Further research is needed to elucidate the mechanisms of these associations.

Modeling sources of listener variability in voice quality assessment is the first step in developing reliable, valid protocols for measuring quality, and provides insight into the reasons that listeners disagree in their quality assessments. This study examined the adequacy of one such model by quantifying the contributions of four factors to interrater variability: instability of listeners' internal standards for different qualities, difficulties isolating individual attributes in voice patterns, scale resolution, and the magnitude of the attribute being measured. One hundred twenty listeners in six experiments assessed vocal quality in tasks that differed in scale resolution, in the presence/absence of comparison stimuli, and in the extent to which the comparison stimuli (if present) matched the target voices. These factors accounted for 84.2% of the variance in the likelihood that listeners would agree exactly in their assessments. Providing listeners with comparison stimuli that matched the target voices doubled the likelihood that they would agree exactly. Listeners also agreed significantly better when assessing quality on continuous versus six-point scales. These results indicate that interrater variability is an issue of task design, not of listener unreliability.

Concurrent chemoradiation therapy (CCRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell death 1 (PD-1) axis inhibitors with radiotherapy are in development for patients with LA-NSCLC. However, the effect of CCRT on programmed cell death ligand-1 (PD-L1) expression on tumor cells is unknown. In this study, we analysed paired NSCLC specimens that had been obtained pre- and post-CCRT. PD-L1 expression on tumor cells was studied by immunohistochemistry. A total of 45 patients with LA-NSCLC were included, among which there were sufficient pre- and post-CCRT specimens in 35 patients. Overall, the percentage of tumor cells with PD-L1 expression significantly decreased between pre- and post-CCRT specimens (P = 0.024). Sixteen, 15, and 4 patients had decreased, unchanged, or increased PD-L1 expression after CCRT, respectively. Median OS of patients with decreased, unchanged, or increased PD-L1 expression was 85.1, 92.8, and 14.6 months, respectively (P < 0.001). In conclusion, the percentage of PD-L1-positive tumor cells significantly decreased after CCRT. Alteration of PD-L1 expression after neoadjuvant CCRT was associated with prognosis in patients with LA-NSCLC. These data should be considered when developing the optimal approach of integrating PD-1 axis inhibitors with CCRT.

No abstract

No abstract